124 terminated. 124 Phase 2, 38 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 124 | Terminated 124 |
| Phase 1 | 38 | Terminated 38 |
| Phase 3 | 3 | Terminated 3 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) - Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Terminated | CARGO Therapeutics | 101 | 2023-08-01 | 2025-05-15 |
| A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies ONCT-808, Bridging Therapy - Relapsed/Refractory Aggressive B-Cell Malignancies | Phase 1 / Phase 2 | Terminated | Oncternal Therapeutics, Inc | 9 | 2023-05-09 | 2024-12-05 |
| Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma Epcoritamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Genmab | 111 | 2023-03-06 | 2026-10-23 |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg - Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Terminated | Nektar Therapeutics | 15 | 2023-02-23 | 2026-10-16 |
| Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma Polatuzumab vedotin (PV), Rituximab, Hyaluronidase - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 5 | 2023-02-17 | 2026-04-16 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies BN301 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | BioNova Pharmaceuticals (Shanghai) LTD. | 9 | 2022-11-25 | 2024-02-21 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-13 | 2026-06-26 |
| Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL GDA-201 - Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Gamida Cell ltd | 13 | 2022-07-05 | 2025-03-25 |
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine, Rituximab - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 41 | 2022-06-21 | 2025-01-30 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma GLPG5101 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | Phase 1 / Phase 2 | Terminated | Lakefront Biotherapeutics NV | 130 | 2022-03-09 | 2026-06-30 |
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] THOR-707, Pembrolizumab - Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Sanofi | 14 | 2021-12-07 | 2025-12-24 |
| Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS Glucarpidase 1000 UNT [Voraxaze] - Diffuse Large B-Cell Lymphoma, Drug Toxicity | Phase 2 | Terminated | Fundacion CRIS de Investigación para Vencer el Cáncer | 3 | 2021-07-19 | 2024-05-13 |
| Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma Belantamab Mafodotin - Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 2 | Terminated | Jacob Soumerai, MD | 10 | 2021-07-01 | 2026-03-13 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma ME-401, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Deepa Jagadeesh | 13 | 2021-04-28 | 2025-02-07 |
Showing 20 of 124. Sign in to see all of them.
Lymphoma (48) · Lymphoma, Non-Hodgkin (48) · Lymphoma, Follicular (47) · Lymphoma, Mantle-Cell (47) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Lymphoma, B-Cell, Marginal Zone (30) · Burkitt Lymphoma (29) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Hodgkin Disease (23) · Recurrence (22) · Lymphoma, B-Cell (21) · Lymphoma, Large-Cell, Immunoblastic (19) · Waldenstrom Macroglobulinemia (19) · Leukemia (17)
Hemic and Lymphatic Diseases (124) · Neoplasms by Histologic Type (121) · Immune System Diseases (120) · Immunoproliferative Disorders (119) · Lymphatic Diseases (118) · Lymphoproliferative Disorders (118) · Neoplasms (115) · Lymphoma, B-Cell (103) · Lymphoma (76) · Lymphoma, Non-Hodgkin (76) · Disease Attributes (54) · Pathologic Processes (54) · Pathological Conditions, Signs and Symptoms (54) · Hematologic Diseases (51) · Leukemia, Lymphoid (48)
Rituximab (40) · Cyclophosphamide (22) · Antilymphocyte Serum (10) · fludarabine phosphate (10) · Doxorubicin (9) · Lenalidomide (9) · Mycophenolic Acid (9) · Prednisone (9) · Vincristine (9) · Etoposide (8) · Tacrolimus (8) · Cyclosporine (7) · Carboplatin (6) · Filgrastim (6) · Gemcitabine (6)
National Cancer Institute (NCI) (11) · Fred Hutchinson Cancer Center (4) · Seagen Inc. (4) · Genmab (3) · Masonic Cancer Center, University of Minnesota (3) · Northwestern University (3) · OHSU Knight Cancer Institute (3) · ADC Therapeutics S.A. (2) · City of Hope Medical Center (2) · Fondazione Italiana Linfomi - ETS (2) · Gilead Sciences (2) · Hoffmann-La Roche (2) · Incyte Corporation (2) · Massachusetts General Hospital (2) · Molecular Templates, Inc. (2)
United States (101) · Spain (15) · France (13) · Italy (13) · Belgium (9) · Australia (8) · United Kingdom (8) · Poland (7) · Canada (6) · South Korea (6) · Germany (5) · Netherlands (5) · China (4) · Czechia (4) · Israel (3)
Ajay Gopal (2) · Reem Karmali, MD (2) · Scott R. Solomon, MD (2) · Stephen D. Smith (2) · Adam Petrich, MD (1) · Adolfo De la Fuente, PD (1) · Alessandra Micozzi (1) · Andrew Spencer, MD (1) · Andrew Zelenetz, MD, PhD (1) · Andy Davies (1) · Anne W. Beaven, MD (1) · Asad Bashey, MD, PhD (1)
PMID 31527168, PMID 19139736, PMID 23782682, PMID 24241210, PMID 25651427, PMID 25696919, PMID 26968534, PMID 29141948, PMID 30795996, PMID 31471376, PMID 33171487, PMID 33559286, PMID 33683917, PMID 34398557, PMID 34515338, PMID 36821767, PMID 38517235, PMID 41043099, PMID 42285113, PMID 42660131
2016 (4), 2023 (4), P30CA015704 (3), 2009 (2), N01CM17003 (2), N01CM62202 (2), P30CA014599 (2), P30CA016058 (2), U10CA021115 (2), U10CA032102 (2), 2014 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1)